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Abstract 
Paraproteinaemic neuropathies are a heterogeneous group of disorders most frequently associated 
with IgM monoclonal gammopathies including Waldenström macroglobulinaemia (WM). Their 
consequences are significant and challenging for affected patients and identification and treatment not 
straightforward for their physicians. The variability of clinical presentation and progression as well as 
the attribution of causality hamper classification and management. The indications for invasive 
investigations such as CSF analysis, nerve conduction tests and sensory nerve biopsies remain 
unclear, as does the optimal way to measure clinical response to therapeutic interventions. When to 
intervene and in whom also present challenges to physicians. As part of its latest deliberations 
(International Workshops on WM, London, UK, August 2014), the IWWM8 panel have proposed a 
consensus approach to the diagnosis and management of peripheral neuropathies associated with IgM 
monoclonal gammopathies, including WM. Importantly, a consensus regarding the use of clinical 
outcome measures and recommended models of care for this group of patients is discussed, as well as 
appropriate treatment interventions. 
 
  




IgM paraprotein-associated neuropathies are a heterogeneous group of disorders whose exact 
prevalence is unknown. Their consequences are significant and challenging for patients and 
physicians alike with no consensus regarding clinical evaluation and optimal baseline assessment.  
The International Workshops on Waldenström’s Macroglobulinaemia (IWWM) have proposed 
criteria for diagnosis and therapy in WM patients (Owen, et al 2003), response (Owen, et al 2013), 
and treatment (Dimopoulos, et al 2014). As part of its latest consensus deliberations (IWWM8, 
London 2014), the panel reviewed the management of peripheral neuropathies (PN) associated with 
IgM monoclonal gammopathies, including WM. 
The prevalence of peripheral neuropathy (PN) in persons with MGUS is approximately 5% in IgG, 
15% in IgA and possibly up to 30-50% in IgM MGUS (Gosselin, et al 1991, Kissel and Mendell 
1996, Nobile-Orazio, et al 1984, Yeung, et al 1991), although this high prevalence rate probably 
reflects patient selection bias in specialist settings and sensitive identification of sub-clinical cases 
(Dispenzieri and Kyle 2005). Monoclonal gammopathies are common with a prevalence of 1% of the 
general population aged 50 and increasing to 8-9% by the age of 90 (Kyle, et al 2006). Peripheral 
neuropathy affects 2.4% of the general population, increasing to 8.0% with advancing age (Martyn 
and Hughes 1997). A frequent challenge when 2 such common conditions coexist, is to relate the 
causality of the MGUS versus coincidental association.  
High quality evidence links at least 50% of the demyelinating neuropathies to a causal IgM 
paraprotein, including antibody transfer models (Tatum 1993, Willison, et al 1993), high titre IgM 
antibodies with a neural target (myelin associated glycoprotein (MAG)), site specific binding studies 
by light and immunoelectron microscopy, a unique pathological substrate (widely spaced myelin) and 
a response to treatment to reduce paraprotein levels. Other antibody targets have been proposed and 
identified in a small number of cases (for example gangliosides GM1 and GD1b, and sulphatide), and 
more are postulated. 
The presence of a neuropathy alone is not a justification for treatment, but steady progression with 
accumulating disability should prompt action. There is little evidence to recommend specific therapies 
(Rajabally 2011); outcomes of clinical trials are hampered by few appropriate participants for trial 
inclusion, their heterogeneity and use of ordinal multi-item composite outcome measures that lack 
reliability, validity and responsiveness (DeVellis 2006, Merkies, et al 2012).  
 
  





As with any diagnostic evaluation, items of diagnostic or therapeutic usefulness appear through the 
assessment and together assist a final decision. We first present the broad concepts of diagnostic 
evaluation, before discussing specifics relating to each diagnosis below. 
Neurological evaluation of a PN accompanied by a paraprotein is best achieved with parallel 
investigation to establish the nature of the IgM monoclonal gammopathy as MGUS, asymptomatic or 
symptomatic WM (Table 1). In this document, the use of the terms IgM MGUS, asymptomatic WM 
and symptomatic WM are based on the clinicopathological definition of WM according to the 
consensus panel recommendations from the Second International Workshop on Waldenstrom's 
Macroglobulinemia (Owen, et al 2003). A history and examination will delineate the important 
clinical features of the PN and are key to further appropriate testing and management (Table 2). It is 
important to identify alternative causes of neuropathy such as diabetes, nutritional deficiencies and 
alcohol, connective tissue disease, drugs (the majority are axonal, rather than demyelinating) or pre-
existent hereditary neuropathy. The nature of the PN symptoms, including speed of onset, clinical 
course, rate of change and effect on functional abilities, as well as the involvement of motor, sensory 
and autonomic systems assists the differential diagnosis and subsequent decision making. The 
conclusions from these investigations, based on a discussion between a haematologist and neurologist 
provides a foundation to establish whether the PN is likely related to the monoclonal gammopathy and 
whether there is a need for treatment. 
 
Nerve conduction tests and electromyography 
 
Electrical tests including nerve conduction studies (NCS) and electromyography (EMG) are an 
extension of the clinical examination and characterise the nature, pattern and extent of nerve damage. 
Evidence for demyelination and/or axonal damage should be determined by standard criteria (1991). 
Features indicative of axonal and demyelinating neuropathy are shown in Table 3.  
Electrophysiological features associated with IgM-associated PN include uniform symmetrical 
reduction of conduction velocities; more severe sensory than motor involvement; disproportionately 
prolonged distal motor latency (DML) and absent sural potentials. Partial motor conduction block and 
marked distal CMAP dispersion are very rare (Joint Task Force of the and the 2006). Specific features 
of the different paraprotein associated neuropathies are delineated below in each section.  
 
It is important to pose a specific question or have a discussion with the neurophysiologist when 
requesting NCS to permit modification of the examination for maximal yield. The implantation of 
some cardiac pacemakers may contraindicate NCS, as life threatening events can be triggered by an 
external voltage applied in close proximity to an implantable cardioverter/defibrillator device. 
Anticoagulants are associated with a risk of intramuscular haematoma with EMG needling; 
anticoagulants might need to be suspended prior to an examination. 
Recommendations: 
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 Neurophysiological testing is recommended where a neuropathy is identified on clinical 
examination to clarify the nature of the neuropathy and expand or curtail investigation. 
 Specific clinical questions should be included in the request for neurophysiological studies to 
allow for appropriate modifications by the neurophysiologist. 
 The results of neurophysiological testing should be assessed in conjunction with the clinical 
picture and the haematological context (MGUS, asymptomatic, symptomatic WM) in order 
for meaningful and practical conclusions to be drawn, and how this influences the 
management of the patient, 
 Relevant steps should be taken to minimise the risk to the patient on anticoagulants or with a 




CSF protein (normal range usually 0.15-0.45g/l) is significantly elevated (>1.0 g/L) in up to 80% of 
demyelinating paraproteinaemic neuropathies (Notermans, et al 2000); in these cases, the effect of the 
IgM antibody is most likely to be humoral attack. In other cases, the clinical picture is of painful 
patchy nerve dysfunction or progressive involvement of nerve roots suggestive of infiltration.  Where 
relevant symptomatology is present, such as an asymmetrical or mononeuritis multiplex pattern, 
infiltration of the peripheral nerves may be the cause, as humoral mechanisms typically result in a 
symmetrical length-dependent neuropathy. If neurolymphomatosis is suspected, biopsy of possibly 
affected nerves is often not feasible, so in this situation, the judicious use of lumbar puncture for CSF 
examination combined with appropriate imaging (PET-CT and/or gadolinium-enhanced MRI) may 
help to confirm the diagnosis (Shaikh, et al 2015). If the clinical examination is in keeping with CNS 
disease, then the presence of malignant cells in the CSF should be sought by immunocytology and/or 
flow cytometry. A single large volume (10 ml) CSF sample will have a 50% chance of identifying 
pathological cells; three consequtive10 ml samples increases the pick-up rate to about 90%.  
Recommendations: 
 
 In cases of demyelinating neuropathy, although not mandatory, examination of the CSF 
supports the diagnosis if the protein is raised and other biochemical constituents are normal.  
 When the clinical work up is unrevealing or inconclusive, and a malignant meningitis or 
invasion of the CNS is suspected, (repeated) examination of the CSF is indicated for cellular 
constituents.  
 If cellular material is identified, then cytological examination and/or immunophenotyping is 
indicated to characterize the cellular population. 
Nerve Biopsy 
 
The indications for nerve biopsy are limited. Sensory nerve biopsies are invasive and associated with 
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a permanent sensory deficit and a 10-20% risk of post biopsy pain. There are limited sensory nerves 
available for biopsy because of anatomy, normal control specimens or affectation. 
However, if a comprehensive clinical work up fails to identify a cause in the presence of a progressive 
and debilitating PN, and/or amyloidosis, vasculitis or direct nervous system invasion is suspected, a 
sensory nerve biopsy is recommended, if possible in a centre with experience in procuring and 
analysing the biopsy. In suspected amyloidosis, alternative sites for biopsy such as bone marrow, 
abdominal fat or rectum should be explored first. Where histological evidence for amyloid has been 
found in other tissues and the clinical and neurophysiological characteristics of the PN are compatible 
with amyloidosis, a nerve biopsy is usually not required.  
Congo red staining identifies amyloid, which can be further sub classified by immunohistochemistry 
(Thomas and King 1974) or mass spectrometry (Klein, et al 2011) where available to identify 
immunoglobulin light chain or familial types, for example transthyretin (the most common). In case 
of suspected lymphomatous infiltration, immunohistochemical staining for monoclonal B cell surface 
markers is mandatory, although the diagnostic yield is often low due to the small sample size. 
Recommendations: 
 
 Where a comprehensive systemic work up has failed to identify a cause and there remains a 
suspicion of amyloid, vasculitis or direct cellular invasion, in atypical cases unresponsive to 
treatment, or progressive, debilitating conditions, a sensory nerve biopsy may be indicated.  
 The risk-benefit ratio of carrying out the biopsy needs to be carefully weighed, if the 
procedure is likely to alter the course of management, it should be performed. 
 The need for a nerve biopsy should be ratified by a neurologist with a specialist interest in PN 




Full thickness skin biopsy samples may be useful for histological confirmation of a small fibre 
neuropathy. Procedural risks of a punch biopsy are very low, and complications are rare. Epidermal 
nerve fibre density is abnormally decreased in only two-thirds of patients suspected of having small 
fibre neuropathy (Periquet, et al 1999). Dermal fibre analysis is developing in usefulness for 




 Skin biopsy is not routinely recommended. A normal skin biopsy does not rule out a small 
fibre neuropathy and the test rarely provides information that alters the management of the 
patient. 





MRI should ideally be performed prior to a diagnostic lumbar puncture (LP) for CSF analysis, as 
false-positive leptomeningeal enhancement may result from LP-related meningeal irritation. 
Specific MR sequences with or without gadolinium enhancement of the neuraxis is indicated in cases 
of suspected neural compression, leptomeningeal or radicular infiltration (Keraliya, et al 2015) or 
where peripheral and central nervous system (CNS) features are present in the clinical examination. 
Focal neurological signs of motor, sensory or higher function are indicative of possible brain 
involvement visualised as parenchymal lesions on MRI images, the so called Bing-Neel syndrome 
(Castillo, et al). Progressive, sequential root or cranial nerve involvement, radicular pain or symptoms 
of meningism are indicative of meningeal involvement and may be identified with leptomeningeal, 
subependymal or dural enhancement, cranial nerve enlargement and enhancement. Spinal MRI can 
reveal enhancing intradural soft tissue, thickening and enhancement of nerve roots and 
leptomeningeal enhancement (Haldorsen, et al 2011). Lymphomatous infiltration of individual nerves, 
spinal roots, cranial nerves or plexi is characterised by nodular or diffuse thickening of nerves which 
usually enhance with contrast (Grisariu, et al 2010). Ultrasound scanning can identify focal and more 




 MRI of the neuraxis should be performed prior to lumbar puncture to avoid false positive 
meningeal enhancement. 
 Prior discussion of likely sites of involvement with an experienced neuroradiologist will 
ensure that the correct sequences of the correct anatomical area are performed with 
appropriate Gadolinium enhancement. 
 MRI, CT and Ultrasound have little ability to differentiate the nature of individual nerve 
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Clinical Phenotypes and their treatment 
 
The paraprotein-associated neuropathies fall into a number of identifiable clinical groups, in which 
the paraprotein is considered causal. Where a causal association is suspected, the following statements 
can act as a useful guide: 
 In the presence of an IgM MGUS or WM and high titres of anti-MAG antibodies, a causal 
relationship between the paraprotein and a demyelinating PN is highly probable (high quality 
evidence).  
 An IgM paraprotein with high titres of IgM antibodies to other neural antigens (such as 
GD1a, GD1b, GM2) and a slowly progressive predominantly distal neuropathy may be 
causally associated (low quality evidence). 
 An IgM paraprotein with a high titre of anti-GM1 associated with a multifocal motor 
neuropathy is likely to be causally linked (moderate quality evidence). 
 An IgM paraprotein with a high titre of antibodies against disialyated gangliosides (GQ1b, 
GT1a, GT1b, GD1b, GD2 and GD3) and a neuropathy with ophthalmoplegia and ataxia 
(CANOMAD) is likely associated (high quality evidence).  
A causal antibody relationship is less likely in IgM MGUS cases where: 
 The neuropathy is axonal. 
 Time to peak of PN <6 months; most antibody targeted paraprotein associated neuropathy is 
slowly progressive. Amyloid, vasculitis or other incidental neuropathy is more likely.  
 The neuropathy has a relapsing and remitting course (spontaneous or to prednisolone/IVIG 
treatment) which is more suggestive of chronic inflammatory demyelinating 
polyradiculoneuropathy (CIDP)) 
 There is cranial nerve involvement (except CANOMAD) – more likely meningeal (cellular 
infiltration), amyloid (light chain infiltration), vasculitic, CIDP, infectious, idiopathic.  
 Non-symmetrical distribution (consider vasculitis, infiltration, diabetes, pressure palsies) 
 History of infection 10 days to 6 weeks preceding the onset (GBS, polio and other viral 
neuroinvasive diseases, HIV, diphtheria, Lyme disease, leprosy). 
 A lambda light chain is present and systemic symptoms suggestive of possible POEMS 
syndrome are identified. 
 
In the following section, the most common clinical entities will be addressed. A schematic decision 
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IgM MGUS-associated peripheral neuropathy without antibodies (Distal acquired 
demyelinating sensorimotor neuropathy) PN 
 
The typical clinical phenotype of antibody-negative PN seen in the setting of IgM MGUS is a 
predominantly distal, chronic (>6 months), symmetrical, painless neuropathy with a predominance of 
sensory symptoms, accompanied by imbalance or ataxia, tremor (up to 89% at onset, 15% disabling) 
and mild or minimal weakness and demyelination on electrophysiological studies (Nobile-Orazio, et 
al 2000, Smith 1994)This phenotype is so characteristic, that the acronym DADS (Distal, Acquired, 
Demyelinating, Sensory-neuropathy) has been coined to capture its features. While the DADS phenotype is 
most commonly associated with anti-MAG antibodies (Katz, et al 2000) (see below), some patients 
may have more prominent ataxia and others proximal weakness reminiscent of CIDP (Katz, et al 
2000).  
Antibody targets for the paraprotein are seldom found but the uniform clinical picture is well 
recognised and the link is presumed, likely constituting one of the "IgM-related disorders" within the 
criteria proposed by Owen et al (Owen, et al 2003).  
 
Rapid progression, a mixed axonal and demyelinating or an axonal predominant PN should raise the 
possibility of primary (AL) amyloidosis, especially if neuropathic pain or autonomic dysfunction are 
present (Vital, et al 2004) or cryoglobulinaemia (Gemignani, et al 2005) if appropriate features are 
present.  
A number of studies of anti-MAG-negative IgM-associated PN have been reported. Response to 
immunotherapy approaches including intravenous immunoglobulin (IVIG), corticosteroids, plasma 
exchange, or a combination is poorer in IgM-PN/DADS than idiopathic CIDP (Larue, et al 2011, 
Simmons, et al 1993a). Although short-term improvement has been shown, no long term benefit has 
been shown for IVIG in IgM MGUS-associated PN (Comi, et al 2002, Dalakas 1996).  
Although these approaches have not been tested prospectively, in patients with rapid worsening 
neuropathy a trial of IVIG, steroids or plasma exchange may prevent irreversible disability in case the 
IgM is irrelevant. Other agents including chlorambucil and interferon-alpha have not been pursued 
beyond early studies because of toxicity and lack of perceived effect or no benefit in trials (Mariette, 
et al 2000, Oksenhendler, et al 1995) 
Recommendations 
 
 In patients without significant disability or haematological reason for treatment, there is no 
indication for immunosuppressive or immunomodulatory treatment, but ongoing surveillance 
is recommended to detect change that requires intervention.  
 Conversely, in patients with significant or progressive disability associated with a 
demyelinating non-MAG associated IgM MGUS with a co-existent neuropathy, 
immunosuppressive or immunomodulatory treatment may be considered.  
 In treated patients who are unresponsive to measures such as IVIG, steroids or plasma 
exchange, agents such as rituximab, in combinations with alkylators, purine analogues and 
steroids should be considered after discussion between a neurologist and a haematologist. 
 Symptomatic treatment for tremor (propranolol, clonazepam, topiramate, gabapentin, 
barbiturates, botulinum toxin) and paraesthesia (gabapentinoids, tricyclic or newer 
antidepressant drugs) should be considered, and reassurance that symptoms are unlikely to 
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worsen significantly for years. Such patients should remain under review to identify evidence 
for clinical evolution. 
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Anti-MAG antibody-associated PN 
 
Up to 50% of patients with IgM-associated demyelinating PN have anti-myelin associated 
glycoprotein (MAG) antibodies, far more commonly IgMκ rather than λ (Nobile-Orazio, et al 1994) 
either in the setting of IgM MGUS or WM(Baldini, et al 1994). Men are more often affected than 
women and from unsteadiness, tremor or sometimes distal weakness the typical age of onset is in the 
7th decade and the course of the disease is insidious. In up to 50% patients, significant disability 
develops 10-15 years following the diagnosis (Nobile-Orazio, et al 2000).  
All patients with IgM-associated demyelinating PN should be tested for anti-MAG antibodies. A 
clinically significant result is ‘strongly positive’ (for example > 70000 Bühlmann units (BTU)). 
‘Weakly positive’ (1000 – 7000 BTU) or ‘positive’ (7000 - 70000 BTU) anti-MAG antibodies are less 
specific for typical anti-MAG neuropathy and may occur in the absence of a PN or alongside an 
unconnected neuropathy. Low titres of anti-MAG IgM (1:200 or less) have been detected in 17 of 101 
control patients without IgM M-proteins (Nobile-Orazio, et al 1989).  
If the anti-MAG assay is negative in the presence of an IgM-associated PN, testing for IgM antibodies 
against other neural targets including the gangliosides GM1, GD1a, GD1b, GT1b, GM2 and GM3 and 
the paragloboside SGPG should be undertaken. Positive results may be supportive of a link between 
the paraprotein and the PN. If these antibodies are present, the probability of an association is 
increased but not proven. GM1 antibodies may be causally associated with a multifocal motor 
neuropathy, as can IgM GD1b antibodies. IgM disialosyl antibodies associate with CANOMAD (see 
below). Of IgM-related demyelinating neuropathies, 30-40% still have no identifiable antibody.  
The electrophysiological features associated with anti-MAG IgM demyelinating PN are readily 
recognisable with slowing of the main trunk velocity but disproportionate prolongation of the distal 
motor latency (DML). Conduction block and abnormal temporal dispersion, more typically seen in 
CIDP, are very rare in this setting (Notermans, et al 2000).  
A Cochrane Review summarises the evidence for treatments of IgM anti-MAG neuropathy (Lunn and 
Nobile-Orazio 2012). IVIG may have some limited benefit in the short term (timescale of weeks), but 
this is of little clinical use. Corticosteroids alone are not effective (Nobile-Orazio, et al 2000), but may 
be beneficial in combination with other agents such as cyclophosphamide (Niermeijer, et al 2007). 
The purine analogues have demonstrated a modest improvement in some studies (Ghosh, et al 2002, 
Niermeijer, et al 2006), and although tolerance of these agents was reported as good, the studies were 
small. For occasional patients with rapidly worsening neuropathy especially with signs of motor 
disability, combinations of active agents or even high dose therapy have been attempted. 
There are several non-randomised studies of rituximab in anti-MAG-associated PN many reporting 
positive benefit in small groups of patients (Briani, et al 2011, Hospital, et al 2013, Renaud, et al 
2006, Renaud, et al 2003, Zara, et al 2011). Five published studies reported a worsening of the PN 
following rituximab (Broglio and Lauria 2005, Gironi, et al 2006, Sala, et al 2014, Stork, et al 2013, 
Weiss and Becker 2014). In the largest report (10 patients) of deterioration (Sala, et al 2014) 
worsening was acute and severe, and occurred during the treatment period, possibly related to an IgM 
flare. All the patients improved after deterioration but at final evaluation only one improved compared 
to baseline, five worsened and four stabilized.  
Two randomised controlled trials of rituximab have been negative in their primary outcome measures, 
but the trials were both underpowered and the outcome measures inadequate (Dalakas, et al 2009, 
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Leger, et al 2013). Secondary outcome measures including patient impression of change were positive 
and a Cochrane Systematic review containing a meta-analysis highlights significant therapeutic 
benefit  {Lunn and Nobile-Orazio in press}.   
.  
Factors predictive of a response to rituximab in anti-MAG neuropathy remain to be elucidated. Short 
disease duration (less than 2 years), active progression at time of treatment and preservation of nerve 
density in biopsies might predict response (Treon SP 2010). Anti-MAG titres and levels of IgM 
paraprotein are neither related to the severity of neuropathy nor predictive of response to treatment. It 
has been suggested that a significant drop in antibody titres might be necessary to achieve a response 
but the depth of optimal haematological remission is not known (Benedetti, et al 2007). Complete 
elimination of the clonal IgM is probably not practical or possible. 
Stability rather than improvement is the most likely outcome of treatment although rare dramatic 
improvements are reported. 
Recommendation:  
 
 There is moderate quality evidence that rituximab is of benefit in the treatment of anti-MAG 
demyelinating neuropathy. The standard dose of 375mg/m2 administered weekly for 4 weeks 
as used in most studies is recommended.  
 In patients with significant or progressive disability associated with a demyelinating anti- 
MAG associated IgM MGUS with a co-existent neuropathy, immunosuppressive or 
immunomodulatory treatment may be considered as an alternative to Rituximab depending on 
availability, comorbidity and patient preference. 
 Measurably progressive disease causing disability is an indication to consider definitive 
treatment given earlier (<2 years from onset where possible) rather than later.    
 Anti-MAG titres and levels of IgM paraprotein are neither related to the severity of 
neuropathy nor predictive of response to treatment. 
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Waldenströms-associated peripheral neuropathy 
 
Symptoms of PN are present in about 20% of patients with WM at diagnosis, and up to 50% are 
affected at some time in the course of their disease (Levine, et al 2006), most often a distal chronic 
symmetrical predominantly sensory polyneuropathy. Nerve conduction studies show evidence of 
demyelination with prolonged DML and reduced conduction velocities in the cases associated with 
MAG antibodies. There are many exceptions with axonal neuropathies or mixed axonal and 
demyelinating neuropathies seen, especially when anti-MAG assay is negative (Viala, et al 2012).  
When significant titres of anti-MAG antibodies (for example ‘strongly positive’ or >70,000 BTU) are 
present, they are probably pathogenic in the WM setting. If atypical clinical or electrophysiological 
features are present, other pathologies including amyloidosis, cryoglobulinaemia, vasculitis or direct 
tumoural invasion of peripheral nerves may be instrumental and appropriate investigations carried out 
as above.  
Where neurotoxic therapy has been used, chemotherapy-induced PN, which is almost always axonal 
with rare exceptions, may be present and will need to be distinguished from WM-associated PN, 
based on the temporal pattern, character and electrophysiology. 
The criteria for the initiation of therapy in symptomatic WM are well established (Dimopoulos, et al 
2014) and include PN due to WM.  
There are no trial data specifically assessing the efficacy of treatment options in WM-associated PN. 
Treon et al reported on the incidence, characteristics and treatment outcome of 199 disease-related PN 
identified in 900 WM patients. Among 122 PN patients evaluated for neuropathic antibodies, 24.5%, 
1.64%, and 0.81% were positive for MAG, GM1, and sulfatide antibodies, respectively (Treon SP 
2010). Thirteen of 61 (21.3%) patients examined for amyloid were confirmed positive. One hundred 
and fifty-one PN patients received chemotherapy comprising an alkylator, purine analogue or 
rituximab; or rituximab / purine analogue combination, cyclophosphamide, thalidomide or 
bortezomib. Of these, 71 (47%) had improvement and 8 (5.3%) had complete resolution of PN 
following therapy. Symptomatic improvement was more likely with non-amyloid related PN, in 
patients who achieved a major haematological response, those who received therapy within 24 months 
of the onset and those who received rituximab combination vs. any monotherapy vs. rituximab alone. 
It is important to be aware that a paradoxical increase in IgM levels following rituximab (‘flare’) 
occurs in 30% to 70% of patients immediately after completing the rituximab course (Treon, et al 
2004) and may be associated with a worsening of existing PN (Noronha, et al 2006), although this has 
been reported to be temporary.   This phenomenon may be severe and resemble an acute inflammatory 
demyelinating neuropathy requiring appropriate management. Appropriate precautions should be 
taken in patients considered at high risk of a flare (IgM > 40 g/L), such as deferring rituximab until 
cycle 2 of combination chemotherapy or performing prior plasma exchange.  
Avoidance of neurotoxic agents is important, although the speed of response to proteasome inhibitor-
containing therapy may outweigh the risk of worsening the PN. Alternative dosing strategies such as 
weekly dosed bortezomib or second generation agents like carfilzomib show promise in this regard 
(Alsina, et al 2012, Treon, et al 2014). Vinca alkaloids have no place in WM patients since they are 
associated with increased neuropathy rates without increasing response rate (Ioakimidis, et al 2009).  
Ibrutinib has shown symptomatic improvement in WM associated PN that progressed after rituximab 
and could also be considered in WM patients with symptomatic IgM related PN (Treon SP 2015). 
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Plasmapheresis (Cortese, et al 2011), corticosteroids and  IVIG are of little or no value (Treon SP 
2010) in the treatment of WM-associated neuropathies.  
WM-related CNS manisfestations, inclduding Bing-Neel Syndrome (Castillo, et al 2016) and 
myelopathy are not within the scope of this review and will be addressed elsewhere. 
Recommendations:  
 
 Patients with slowly progressing WM or PN do not require immediate therapy. 
 Where treatment is required, treatments such as Rituximab, Dexamethasone, 
Cyclophosphamide and Rituximab (DRC), Bendamustine-Rituximab (BR), Carfilzomib, 
Rituximab, Dexamethasone (CARD) or purine analogue combinations are possible  options.  
 When indicated, treatment of appropriate intensity to remit both the systemic disease and the 
neurological component is required.  
 Ibrutinib, where available could be considered in the setting of intolerance of chemotherapy-
based therapies or if previous therapies have failed. 
 Appropriate precautions should be taken in patients considered at high risk of a flare (IgM > 
40 g/L), such as deferring rituximab until cycle 2 of combination chemotherapy or performing 
prior plasma exchange. 
 Avoidance of neurotoxic agents is important; the vinca alkaloids have no place in the 
management of WM, particularly those with PN.  
 Plasmapheresis, corticosteroids and  IVIG are of little or no value in the treatment of WM-
associated neuropathies.  
 
  




Chronic ataxic neuropathy with ophthalmoplegia, M-protein, cold agglutinins and disialosyl 
ganglioside (IgM Anti-GD1b/GT1b/GQ1b) antibodies (CANOMAD) is a rare chronic neuropathy 
which presents as a chronic peripheral sensory ataxia, ophthalmoplegia and sometimes other cranial 
nerve involvement (Willison, et al 2001). NCS show a mixed picture of axonal loss and 
demyelinationng features including very low or absent sensory action potentials and degrees of slow 
motor conduction velocities. It is important to exclude alternative, infiltrative causes of cranial nerve 
abnormalities.  
Clinical improvement has been noted following IVIG and Rituximab (Loscher, et al 2013). 
Recommendations: 
 









AL amyloidosis should always be considered as a possible cause of a paraproteinaemic neuropathy. 
PN is reported as a symptomatic clinical feature in up to 20% of patients with AL amyloidosis, and 
evidence for a subclinical PN is found in 35% of patients (Matsuda, et al 2011, Rajkumar, et al 1998). 
Common presentations include a progressive, painful small fibre predominant length-dependent PN 
which typically starts in the feet, accompanied by an autonomic neuropathy in about 65% of cases 
(Rajkumar, et al 1998). Amyloid causes direct nerve damage through the presumed action of fibrils in 
the endoneurium and the endoneurial vessels. Amyloid can also cause nerve damage by other 
mechanisms for example entrapment neuropathies including carpal tunnel syndrome, and neural or 
radicular tumorous infiltration resulting in multifocal mononeuropathies, lumbosacral or brachial 
radiculopathies and cranial neuropathies in the absence of a polyneuropathy (Matsuda, et al 2011, 
Rajkumar, et al 1998).  
Amyloid is most often a systemic disease with other organ involvement and this is a strong pointer to 
an amyloid PN. Other features should be actively sought, such as cardiac insufficiency and 
arrhythmia, renal impairment with proteinuria, autonomic neuropathy, GI bleeding, macroglossia and 
bleeding diatheses. Early recognition is more likely to curtail irreversible organ damage and reduce 
mortality. Notwithstanding pre-existing co-morbidities,  screening for AL amyloidosis can be 
performed using two biomarkers, serum NT-proBNP and urinary albumin, that detect early 
amyloidosis in 97% of patients (Merlini, et al 2013). Heart damage is a major determinant of survival, 
and staging with cardiac biomarkers guides treatment (Merlini, et al 2014). 
Nerve conduction studies show a symmetrical, axonal sensorimotor neuropathy but occasionally 
patchy presentations or slowing (reported as ‘demyelination’) are found. A definitive diagnosis 
requires the demonstration of amyloid in a tissue. The most accessible and innocuous site is 
periumbilical abdominal fat that shows Congo red positive deposits in 80% of patients (Fernandez de 
Larrea, et al 2015). When combined with similar analysis of bone marrow, the sensitivity reaches 
90% or more. In the rare patients in whom both biopsies are negative, a nerve biopsy might be 
considered. The sensitivity of nerve biopsy for detecting amyloid varies from 30-100% (Simmons, et 
al 1993b), depending upon the size and site of the biopsy and the expertise of the pathologist.  
Urgent measures to suppress the clone responsible for the production of the amyloid protein are 
essential. Where possible, high dose therapy and autologous stem cell transplantation is the treatment 
of choice, resulting in a 53% 10-year survival for those achieving a complete response (Sanchorawala 
and Seldin 2007). Best outcomes are likely to be achieved in centres which specialise in this 
condition. For transplant ineligible patients (75-80% cases), melphalan-dexamethasone (Palladini, et 
al 2007) or bortezomib-based combinations are effective (Merlini, et al 2013). Bortezomib needs to 
be administered with particular caution due to its neurotoxic potential, which can be reduced by 
subcutaneous administration and weekly scheduling. There is minimal evidence for the effect of 
carfilzomib in this setting and there is some concern about possible cardiotoxicity(Atrash, et al 2015). 
For relapsing patients, Lenalidomide (Palladini, et al 2012, Sanchorawala, et al 2013) and 
Pomalidomide (Dispenzieri, et al 2012) are recommended. 
Recommendations 
 Treatment of AL amyloidosis should be risk-adapted and response-tailored and neurotoxic 
agents used with caution.  
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 High dose therapy and autologous stem cell transplantation is the treatment of choice in 
suitable patients and should be carried out in centres with appropriate expertise. 
 Melphalan-dexamethasone or bortezomib-based combinations are recommended in 
transplant-ineligible patients.  
 Lenalidomide and Pomalidomide are a good options for refractory/relapsed patients.  
Small fibre neuropathy 
 
Typical small fibre neuropathy presents with length dependent burning pain beginning in the feet and 
may spread more proximally in a length dependent fashion. Symptoms are worse at night where they 
can disturb sleep resulting in fatigue and increased daytime pain. 
Similar small fibre symptoms, presenting as patchy dermatomal sensory disturbance subsequently 
coalescing are due to small fibre involvement of the sensory ganglia of lesser understood pathology.  
The diagnosis of a small fibre neuropathy is made on the basis of the history; the only clinical sign is 
a length-dependent sensory alteration to pinprick or temperature. This may be patchy with ganglion 
involvement. Investigations to prove small fibre involvement are quantitative sensory tests and skin 
biopsies stained for epidermal nerve fibres (distal small fibre neuropathy) which can be quantified in 
microscopy. 
Treatment is symptomatic with gabapentinoids, tricyclic or newer antidepressants (Hoeijmakers, et al 
2012, Themistocleous, et al 2014). 
Recommendations 
 
 Evidence-based justification for treating a WM or MGUS-associated small fibre neuropathy is 
completely lacking.  
 Treatment is usually symptomatic with tricyclic antidepressants, newer SSRI/SNRI drugs, 
opioids and gabapentinoids (very low quality evidence). 
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Clinical Outcome Measures 
 
Historically, outcome measures have focused on assessment of impairment based on muscle strength 
and sensory testing and disability, using classical test theory derived scales.  
The Medical Research Council (MRC) sum score and the Neuropathy Impairment Score (NIS) sums 
the scores muscles to represent the overall strength of a patient(Dyck, et al 2003). Sensory scores, 
including the Inflammatory Neuropathy Cause and Treatment (INCAT) sensory sum score (ISS) and 
Neuropathy Impairment Sensory score (NISsens) are similarly used to capture the sensory status of a 
patient (Dyck, et al 2005) but these measures require detailed and consistent neurological assessment 
and may not show meaningful changes over time. 
Disability measures have been developed for inflammatory neuropathies, and the overall neuropathy 
limitations score or ONLS (van Nes, et al 2008) is a standard measure for FDA licensing 
requirements. Disability measures more accurately reflect meaningful change in a patient’s condition.   
Rasch Theory-built scales linearly reflect patient function over the whole range of abilities and are 
designed and validated for individual diseases. The Inflammatory Rasch-Built Overall Disability 
Scale (I-RODS) designed as part of the Peripheral Neuropathy Outcome Measurement 
Standardisation (PeriNomS) study (Draak, et al 2014, Merkies, et al 2003, Vanhoutte, et al 2012) is a 
valid disability scale for inflammatory neuropathies which captures meaningful changes over time.  
Recommendations:  
 
 The I-RODS more often captures clinically meaningful changes over time, with a greater 
magnitude of change, compared with the INCAT-ONLS disability scale and its use is 
therefore suggested in future trials involving patients with inflammatory neuropathies.  
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Models of Care 
 
The clinical entities that comprise IgM-associated PNs are managed in a variety of clinical settings, 
by haematologists, oncologists and neurologists. In order to achieve successful outcomes for these 
patients, joint working across disciplines offers a favourable approach that should overcome the 
barriers of working in isolation and risking a failure to perform appropriate diagnostics as well as 
offer optimum therapeutic and supportive input.  
Physical and occupational therapists play a vital role in helping to improve and maintain functions 
that may be limited by PN including exercise intervention to help improve strength (Streckmann, et al 
2014), balance and coordination activities which can help decrease the risk of falling (Riva, et al 
2014). Tailored home exercise is acceptable to individuals with inflammatory neuropathies and is 
associated with significant improvements in activity limitation, fatigue, quality of life and mood 
(White, et al 2015). Patient education can focus on improving safety, preventing injury, and finding 
alternative ways to perform certain tasks. 
Provision of appropriate and well-fitting orthotic supports, can improve the efficiency of movent as 
well as harvesting energy from gait (Alam, et al 2014).  
Recommendations: 
 
 A suggested model of care is a combined neurological and haematological clinic, in which 
patients are seen jointly by a specialist neurologist and haematologist and a decision can be made 
about the sequence of investigations, interventions and the formulation of a treatment plan. 
 Appropriate and timely referral to physical, occupational and orthotic professionals is 
recommended in order to maximise safety and function. 
 
  




A number of biological agents are currently under investigation in WM, may prove particularly suited 
to the treatment of patients with paraproteinaemic neuropathies, given their non-neurotoxic side effect 
profiles.  
Next generation proteasome inhibitors, such as carfilzomib has been assessed in combination with 
rituximab and dexamethasone (Treon, et al 2014) shows an ORR of 87% and a low risk of 
neurotoxicity. Everolimus, an oral mTOR inhibitor (Treon SP 2013) (ORR 72% in the upfront setting) 
has some grade ≥2 adverse events which do not include PN. Other effective agents which have 
favourable side effect profiles in this setting include the BTK inhibitors ibrutinib (Treon, et al 2015), 
acalabrutinib (Wu, et al 2016), and BG -3111 (Constantine Tam 2015) and IMO-8400 (Sheeba K. 
Thomas 2015), an oligonucleotide specifically designed to inhibit toll-like receptor signaling 
pathways, for which MYD88 is a key linker protein. Daratumumab, a human antibody to CD38, has 
also shown encouraging responses (Phipps, et al 2015) and may be particularly suited to those 
instances when the clinical features are a consequence of the M protein such as hyperviscosity and 
neuropathy. 
  




There is much to be done to improve outcomes for patients with IgM and Waldenströms-associated 
peripheral neuropathies. Starting with early recognition of the problem, appropriate causal attribution 
achieved through sensitive diagnostics which are not overly invasive, timely therapeutic intervention 
with effective and non-neurotoxic therapies, achievement of an appropriate degree of clonal reduction 
for optimum clinical outcomes and the use of reproducible and readily applicable tools to measure 
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